Document is current
Any future updates will be listed below
-
Authors
van Doremalen, Neeltje https://orcid.org/0000-0003-4368-6359
Avanzato, Victoria A.
Goldin, Kerry
Feldmann, Friederike https://orcid.org/0000-0002-1363-1077
Schulz, Jonathan E.
Haddock, Elaine https://orcid.org/0000-0002-8260-227X
Okumura, Atsushi
Lovaglio, Jamie https://orcid.org/0000-0002-7567-446X
Hanley, Patrick W.
Cordova, Kathleen
Saturday, Greg https://orcid.org/0000-0002-0803-6177
de Wit, Emmie https://orcid.org/0000-0002-9763-7758
Lambe, Teresa
Gilbert, Sarah C. https://orcid.org/0000-0002-6823-9750
Munster, Vincent J. https://orcid.org/0000-0002-2288-3196
- License Information
-
More Information
Article History
Received: 27 June 2022
Accepted: 6 December 2022
First Online: 21 December 2022
Competing interests
: S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering the use of ChAdOx1-vector-based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and Vaccitech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture, and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor Vaccitech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. The remaining authors declare no competing interests.
